B-cell-directed therapy for chronic graft-versus-host disease.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. The immunological phenotype of rituximab-sensitive chronic graft-versus-host disease: a phase II study.Haematologica · 2011
   Trial
2. Membranous Nephropathy with Crescent after Hematopoietic Cell Transplantation.Internal medicine (Tokyo, Japan) · 2019
   Article
3. Antibodies targeting surface membrane antigens in patients with chronic graft-versus-host disease.Blood · 2017
   Article
4. Treatment of chronic graft-versus-host disease in 2011.Current opinion in hematology · 2011
   Review

Corrections and comments

• Comment on
  Weekly rituximab followed by monthly rituximab treatment for steroid-refractory chronic graft-versus-host disease: results from a prospective, multicenter, phase II study.2010

Authors and funding

2 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as